CMS is recalculating select 2026 Medicare Advantage Star Ratings after a court ruled that the original calculation for Clover Health’s rating was improperly determined. The change could boost payments for a small number of insurers affected by the recalculation. The action is operationally significant for health plans and the biotech ecosystem that depends on Medicare Advantage contracting, as star ratings influence quality bonus structures and plan economics. For companies selling into MA networks or supporting care delivery programs, even limited recalculations can change near-term network negotiations. More broadly, the update highlights how litigation can directly feed into reimbursement mechanics, meaning plans may adjust operational metrics programs ahead of star-rating deadlines while monitoring CMS recalculation details.